View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 1, 2021

Atea’s oral drug reduces viral load in Phase II Covid-19 trial

On day two, subjects in the AT-527 arm had an 80% higher mean reduction from baseline viral load compared with the placebo. 

Atea Pharmaceuticals has reported positive interim data from the Phase II study where its antiviral drug candidate, AT-527, reduced viral load levels in mild-to-moderate Covid-19 patients in the hospital setting.

Co-developed by Atea and Roche, AT-527 is an oral direct-acting antiviral (DAA) agent.

The global, randomised, double-blind, placebo-controlled, multi-centre Phase II trial is analysing the safety, tolerability, clinical and antiviral efficacy of AT-527 in moderate Covid-19 patients.

Within five days of onset of symptoms, the trial subjects were given a twice-daily dose of either AT-527 550mg or placebo for five days.

The interim analysis included findings from 70 high-risk subjects hospitalised with Covid-19, of which 62 were evaluable for virology assessment.

Data showed that AT-527 quickly decreased viral load levels and subjects in the treatment group had an 80% improved mean reduction from baseline viral load versus placebo at day two.

Furthermore, a sustained difference in a drop in viral load levels was maintained till the eighth day.

Nearly 47% of subjects in the AT-527 group and 22% in the placebo arm showed no detectable ribonucleic acid virus by day 14.

In addition, the oral drug was observed to be safe and well-tolerated, which is in line with earlier studies.

No serious adverse events or new safety risks linked to AT-527 were noted in the trial.

Atea Pharmaceuticals founder and CEO Jean-Pierre Sommadossi said: “We are very pleased with the potent antiviral activity of AT-527 demonstrated by the rapid inhibition of SARS-CoV-2 replication.

“Such potent activity may lead to faster recovery time for patients with Covid-19 while minimising the transmission of infection.”

Atea and Roche are currently studying AT-527 in the Phase III MORNINGSKY trial and Phase II MOONSONG virology study in mild or moderate Covid-19 patients in an outpatient setting.

Multi-cohort data from the MOONSONG study is anticipated in the third quarter of this year.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy